<DOC>
	<DOCNO>NCT01376661</DOCNO>
	<brief_summary>The purpose research study monitor feasibility outcome Active Surveillance Program men low risk prostate cancer .</brief_summary>
	<brief_title>Outcome Assessment Active Surveillance Program Low Risk Prostate Cancer : An Observational Study</brief_title>
	<detailed_description>The purpose observational study prospectively monitor outcome associate men meet eligibility criterion low risk prostate cancer elect participate active surveillance program The Center Cancer Prevention Treatment St. Joseph Hospital . We hope demonstrate men compliant closely monitor active surveillance program low risk prostate cancer achieve favorable outcome : 1 ) avoid side effect definitive therapy may necessary ; 2 ) retaining quality life ( QOL ) normal activity ; 3 ) avoid unnecessary treatment ; 4 ) decrease health care cost . In addition , monitor possible adverse outcome may associate active surveillance program include suboptimal response and/or great side effect due delay initiation therapy ; psychological impact patient caregiver due anxiety living untreated cancer and/or requirement frequent medical examination periodic prostate biopsy .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>At least 18 year age Histological document adenocarcinoma prostate either newly diagnose previously diagnose . Subjects diagnose 3 month prior time enrollment active surveillance program must biopsy repeat . PSA &lt; 10 ng/ml within 1 month program enrollment Clinical stage less equal T2a Biopsy sample least 1012 core Gleason score less equal 3 + 3 No 2 core involve No core 50 % involve Eligible definitive therapy Able provide inform consent Able complete QOL questionnaire Able comply schedule followup appointment See inclusion criterion eligibility</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Active Surveillance</keyword>
	<keyword>Low risk prostate cancer</keyword>
</DOC>